To elucidate mechanisms underlying neovascularization that accompanies certain chronic immune/ inflammatory disorders, the effects of interferon-a (IFN-a) and interleukin 2 (IL-2) on endothelial cell (EC) growth in vitro and angiogenesis in vivo were studied. Preincubation of cultured human ECs with IFNa, followed by exposure to IL-2, resulted in effective stimulation of cell growth, whereas either cytokine alone had only a slight effect. The combination of IFN-a/IL-2 induced an angiogenic response in the rabbit cornea. IL-2 receptor expression was enhanced on IFN-a-treated ECs: p55 was increased and p70 was induced. '25I-IL-2 binding to ECs treated with IFN-a was enhanced (Kd from 7 nM to 260 pM with IFN-a), and anti-p55 IgG blocked '25I-IL-2/EC interaction as well as IL-2-mediated EC proliferation. Consistent with these findings in cell culture, immunohistologic studies demonstrated p55 and p70 antigen in the vasculature of rheumatoid joints, but not in normal joint tissue. Exposure of cultured ECs to IFN-a increased levels of intracellular EC basic fibroblast growth factor (bFGF), and subsequent addition of IL-2 led to bFGF release into the medium. The observation that anti-bFGF IgG largely blocked EC proliferation in response to IFN-a/IL-2 suggested that bFGF was a critical agent in this setting. These data suggest a mechanism rendering ECs responsive to IL-2 which may be relevant in immune/inflammatory disorders: IFN-a-mediated induction of functional EC receptors for IL-2, which drives cell proliferation by a mechanism dependent on increased synthesis and release of bFGF. (J. Clin. Invest. 1993. 91:2504-2512
Introduction
Formation of new blood vessels is an ongoing process which subserves multiple different roles spanning early development to promotion oftumor growth ( 1, 2) . The angiogenic response, including endothelial cell (EC)' migration and proliferation, is Sciences, Inc., Ann Arbor, MI) and the radioactivity was determined. Exposure of endothelial cultures to IFN-a/IL-2 did not result in cell lysis during the proliferation studies or radioligand binding experiments (see below). This was assessed by (a) exclusion of trypan blue, (b) no increase in release of lactate dehydrogenase into the culture medium, and (c) the presence of an adherent cell population with no increase in floating cells.
Surface binding and internalization of "MI-labeled cytokines. For IL-2 binding studies, preconfluent cells (106 in six-well plates), cultured in the presence or absence of IFN-a (500 pM) for 24 h, were incubated for 40 min at 370C in 1 ml of medium 199 containing 10% FCS and 0.1% sodium azide, with different concentrations of '25I-IL-2 alone (total binding) or with a 200-fold excess of unlabeled IL-2 (nonspecific binding). Monolayers were then washed extensively with HBSS, and membrane-bound radioactivity was eluted using glycine buffer (0.2 M, pH 2.8) for 45 s at 4VC (neither cell lysis nor detachment occurred during the experiment or the following elution procedure). Specific binding was determined as the difference between total and nonspecific binding, and data were analyzed by nonlinear least-squares analysis using a one-site model in a scientific data analysis program ( For IL-2 internalization studies, preconfluent cells were maintained in control medium for 48 h, stimulated with intact or heat-inactivated IFN-a (0.5 nM) for 18 h, washed twice, and then incubated for 4 h more at 37°C in the same medium with "'I-IL-2 (1 nM), in the presence or absence of 200-fold excess of unlabeled cytokine. At the end of incubation period, cells were washed five times with HBSS. Membrane-bound radioactivity was eluted with glycine buffer as above, and the internalized (i.e., endocytosed) radioactivity was extracted by lysing the cells in PBS containing Triton X-100 ( 1%).
For bFGF binding studies, preconfluent ECs grown in 24-well plates and maintained in control medium for 48 h were cultured for an additional 24 h in the presence of either IFN-a, IFN-a plus IL-2 (0.5 nM each), or heat-inactivated cytokines. Cells were then washed and incubated for 2 h at 4°C in medium 199 supplemented with 0.2% gelatin with different concentrations of '25I-bFGF, in the presence or absence of a 200-fold molar excess of unlabeled bFGF. At the end of incubation period, cultures were washed three times with PBS, once with high-salt buffer (2 M NaCl, 25 mM Hepes, pH 7.2), and then lysed with phosphate buffer (0.1 M, pH 8.1 ) containing Triton X-100; binding data were analyzed as above.
For bFGF internalization studies, cultures were incubated in control medium for 48 h, stimulated with native or heat-inactivated IFN-a for 18 h, and then cells were washed twice with PBS and once with acidic buffer (medium 199 at pH 3.0) for 45 s at 4°C. Next, cells were incubated in control medium containing '25I-bFGF (0.5 nM) in the presence of native or heat-inactivated IL-2 (0.5 nM) for 2 h at 37°C.
Controls for nonspecific uptake of "'I-bFGF also contained 200-fold molar excess ofunlabeled bFGF. At the end ofincubation, membranebound "'I-bFGF was eluted after washing in low-and high-salt buffers (see above), and internalized 125I-bFGF was subsequently released by dissolution of the monolayers with Triton X-100 ( I %; see above).
Biosynthetic labeling and immunoprecipitation studies. To assess expression of IL-2R p55 and p70 chains, and production of bFGF, preconfluent ECs (-3 x 106), maintained in control medium for 48 h, were stimulated with native or heat-inactivated IFN-a (0.5 nM). At the end of the incubation period, cells were rinsed twice in PBS, and then cultured with native or heat-inactivated rIL-2 for an additional 4 In selected experiments, bFGF (35 ,g/ml) was added to both cell lysates and supernatants of labeled EC before and during the incubation with anti-bFGF antibodies. The samples were concentrated with Protein-G-Sepharose and the eluates were analyzed as above.
Pellet preparation and corneal implant. Aliquots of cytokine solutions (IFN-a, 15 mg/ml; IL-2, 10 mg/ml), containing the indicated amounts of IFN-a and/or IL-2, were evaporated to dryness at room temperature. The residual pellet was incorporated into a casting solution of Elvax-40 (10%; Du Pont, Milan) in methylene chloride. The solvent was evaporated, and the repolymerized Elvax-40 pellet was cut into 1 X 1 X 0.5-mm fragments and further evaporated overnight under vacuum at 4VC. The same procedure was followed for the preparation of control pellets with Elvax-40 alone.
Two parallel pockets were surgically produced onto each rabbit cornea as previously described ( 11 To extend these observations in cell culture to the in vivo setting, the angiogenic response induced by IL-2 and IFN-a was assessed in the rabbit cornea model. When studied separately, the two cytokines exhibited different angiogenic properties. IL-2 alone (50 ng) was only marginally effective, producing no response in 75% of the implants, and resulting in only sparse capillary buds, starting from the limbal region and progressing through one third ofthe corneal stroma underlying the pellet (Fig. 2, top) in the remaining 25% of implants (similar results were observed at 100 ng of IL-2). IFN-a (50 ng) was more effective in promoting capillary neoformation, in that 50% of the implanted pellets elicited formation and progression of capillaries that reached the pellet (Fig. 2 , middle) (similar results were observed at 100 ng of IFN-a). When the two cytokines were tested simultaneously (each at 50 ng per pellet), the angiogenic response was far more potent: virtually all implants exhibited neovascularization, and the number and growth rate ofthe newly formed vascular network was dramatically potentiated (Fig. 2, bottom) .
In order to assess the mechanisms through which the combination of IFN-a and IL-2 enhanced EC proliferation, cultures in control medium were preincubated with either IL-2 or IFNa for 18 h, washed with HBSS, and then the effect ofadding the other cytokine was studied over the next 48 h. Cultures exposed to TL-2, and then exposed to IFN-az, showed no increase in [3H I thymidine incorporation above that seen in control medium alone (Fig. 3) . In contrast, preincubation of ECs with IFN-a did enhance the mitogenic response to subsequently added IL-2 (Fig. 3) . The optimal preincubation time of ECs with IFN-a for a maximal mitogenic response on addition of IL-2 was about 24 h (data not shown). These data suggested that IFN-a was priming the ECs to respond to IL-2. Effect ofIFN-a on EC binding sites for IL-2. One means through which IFN-a could alter the effects of IL-2 on ECs would be by modulating endothelial expression ofIL-2 binding sites. Unstimulated EC monolayers incubated with 1251-IL-2 showed dose-dependent binding, half-maximal at 7 nM (Fig. 4) . When ECs were pre-incubated with IFN-a, the affinity of '25I-IL-2 binding increased significantly with Kd 260 pM (Fig. 4) . Inhibition of 1251-IL-2 binding to unstimulated and IFN-a-treated ECs by mAb to p55 demonstrated that the IL-2 receptor was responsible for interaction ofIL-2 with endothelial cultures (Table I) .
Although the affinity of IL-2 for IFN-a-treated ECs was lower than that ofthe high-affinity IL-2 receptors on lymphoid cells (Kd 10 pM) (10), these IL-2 binding sites appeared to be functional, based on three lines of experimental evidence. First, addition of antibody to the IL-2 receptor p55 chain blocked EC proliferation induced by IL-2 in cultures preincubated with IFN-a (Table II) . Second, occupancy of these IL-2 binding sites by ligand (Fig. 4) correlated with IL-2-mediated enhancement of EC proliferation (Fig. 1) . Third, binding of 1251-IL-2 at 370C to ECs pretreated with IFN-a resulted in internalization ofthe tracer: specifically cell-associated 1251-IL-2 was present on the cell surface (eluted in the presence of acidic buffer) and in an internalized pool (released by dissolution of the cells with detergent after removal of surface-bound pool) (data not shown). Resistance of the pool of internalized 125I-IL-2 to elution with acidic buffer was not due to irreversible binding to a cell surface structure, as it was not released by exposure ofcultures to trypsin, and no higher molecular weight complex of ligand with another protein was evident on SDS-PAGE. Thus, it was concluded that this pool of cell-associated 125 Association ofIL-2 receptor p55 and p70 chains with endothelium in vivo. In view of the EC expression of p55 and p70 observed in cell culture, we investigated whether IL-2 receptors could be associated with endothelium in vivo. Our attention was focused on rheumatoid arthritis, a situation in which angiogenesis in the joint space occurs in the context of an abundance of activated lymphoid cells likely to be producing cytokines (7). Indirect immunofluorescence of synovial tissues from a patient with rheumatoid arthritis with mAbs to p55 and p70 antigens demonstrated a focal distribution in the small blood vessels (Fig. 6, A and C) . No p55 or p70 antigen could be detected in joint tissue from normal individuals or a patient with osteoarthritis (data not shown). Although the latter observation would appear to conflict with the constitutive expression of p55 seen in cultured ECs above, it is possible that this represents another change in EC phenotype which occurs when umbilical vein ECs adapt to tissue culture.
Effect ofIFN-a and IL-2 on ECsynthesis, release, and internalization of bFGF. The effectiveness of IL-2 and IFN-a in stimulating EC growth, which was similar in magnitude to the effect of bFGF, suggested the possibility that these cytokines might alter expression/availability of EC bFGF. To test this hypothesis, EC monolayers were pulsed with IFN-a for 18 h, and then proteins were biosynthetically labeled in the presence/absence of IL-2 for 4 h. Analysis of cell lysates precipitated with monospecific polyclonal IgG raised to bFGF demonstrated a band with Mr ; 17 kD in unstimulated ECs (Fig. 7,  left, lane 3) . This band disappeared on addition ofexcess unlabeled bFGF during incubation with the primary antibody (Fig.  7, middle, lanes 1 and 2) . Several other, more slowly migrating bands, immunoprecipitated with anti-bFGF antibodies from ECs, also disappeared on addition of unlabeled bFGF, consistent with previous reports ofhigher Mr forms ofbFGF in endothelium ( 13) . Taken together, these data indicate that the metabolically labeled protein of Mr 17 kD, immunoreactive with anti-bFGF antibodies, was most likely EC-derived bFGF. Levels of metabolically labeled bFGF in cell lysates were increased on exposure of cultures to IFN-a (Fig. 7, left, lane 2) .
In contrast to the rise in bFGF levels induced by IFN-a, subsequent addition ofIL-2 led to a decrease in immunoprecipitable bFGF in cell lysates (Fig. 7, left, lane 1) . The apparent reason for this decrease in intracellular bFGF was evident from SDS-PAGE analysis of culture supernatants from IFN-a/IL-2-stimulated ECs (Fig. 7, right) : although bFGF was undetectable in medium from quiescent cultures (Fig. 7, right, lane 1) , and was barely detectable in IFN-a-treated cells (Fig. 7 , right, lane 2), considerable amounts of bFGF were present in the medium from ECs exposed sequentially to IFN-a and IL-2 (Fig. 7, right, lane 3) . The likely identity of metabolically labeled protein with Mr 17 kD in the supernatant of IFN-a/ IL-2-treated ECs with bFGF was emphasized by its disappearance in the presence of excess unlabeled bFGF (data not shown).
These data support the hypothesis that IFN-a and IL-2 drive EC proliferation via enhancing EC synthesis and release of bFGF. To test this directly, ECs were stimulated with IFN-a and IL-2 in the presence of neutralizing anti-bFGF IgG (Table  III) . IFN-a/IL-2-enhanced proliferation was blocked by 50- * Preconfluent ECs were maintained in control medium for 48 h, then IFN-a (0.5 nM) was added for 24 h, followed by either no further addition (Nil) or the addition of IL-2 (50 pM or 0.5 nM), alone (medium) or in the presence of rabbit anti-bFGF IgG (10 /iLg/ml), or control rabbit IgG (10 ,gg/ml) for 48 h.
[3H]thymidine incorporation was determined as described in the text. Data shown are the means of triplicate determinations (SD was always < 10%). One experiment representative of three performed is shown. 60% by antibody to bFGF (10 ,ug/ml), whereas nonimmune IgG was ineffective. Although higher concentrations of antibFGF antibodies (50 ,ugg/ml) completely blocked IFN-a/IL-2-mediated stimulation ofEC proliferation (and preimmune IgG at the same concentration was without effect), these levels of anti-bFGF IgG resulted in a looser attachment of ECs to the growth substrate, leading to a variable cell loss during washing procedures and less reproducible results. * Preconfluent ECs were maintained in control medium for 48 h, and were then exposed to control medium containing either no further additions (Nil), IFN-a (0.5 nM), or IFN-a + IL-2 (each at 0.5 nM) for 24 h. Cultures were then washed and radioligand binding assays were performed at 4°C with '25I-bFGF in the presence/absence of excess unlabeled bFGF, as described in the text. Specifically bound '25I-bFGF versus free/added '25I-bFGF was analyzed by nonlinear least squares analysis using a one-site model. Binding parameters are shown above for each of the three conditions.
To further probe the effect of IFN-a and IL-2 on the interaction of bFGF with ECs, radioligand binding experiments were performed with 1251-bFGF at 40C. The results showed that neither the affinity nor the total number of EC binding sites for bFGF was significantly altered by IFN-a alone or IFN-a/IL-2 (Table IV) . In contrast, internalization of 1251-bFGF at 370C was enhanced in ECs which had been exposed to both cytokines (Fig. 8) . Endocytosed or internalized 1251I-bFGF was defined as that pool of specifically cell-associated radioligand (i.e., total '25I-bFGF minus nonspecifically cell-associated 12511 bFGF, the latter defined as that observed in the presence of excess unlabeled bFGF) remaining bound after elution of the surface-associated pool by an acid wash (14) . Quiescent cultures internalized only small amounts of '25I-bFGF, and cultures preincubated with either IFN-a or IL-2 alone showed uptake of only slightly greater amounts of bFGF. However, ECs exposed to both cytokines internalized enhanced amounts of '251-bFGF (Fig. 8) . Control experiments under the same conditions with acetylated LDL did not demonstrate increased cellular uptake, suggesting that enhanced receptor-mediated endocytosis ofbFGF by ECs treated with IFN-a/IL-2 was not a general finding for all EC receptor-ligand interaction (data not shown).
Discussion
The findings reported here indicate that ECs exposed to IFN-a become responsive to the mitogenic effects of IL-2. Although prior studies have described a direct effect of IL-2 alone on cultured ECs, in terms ofprostacyclin release, increased permeability, and, under certain circumstances, also cell proliferation (15) (16) (17) , in our studies IL-2-mediated stimulation of EC growth required endothelial activation, brought about by IFNa. Consistent with this interpretation, IFN-a-treated ECs demonstrated a close correlation between concentrations of IL-2 which induced EC proliferation and those which resulted in occupancy of endothelial IL-2 binding sites, and internalization of EC surface-bound IL-2 occurred only after exposure to IFN-a. The means through which IFN-a exerted its EC effects in this context appeared to involve, at least in part, enhanced expression of the p55 chain (whose constitutive expression by cultured ECs had been previously reported [ 17 ] ) and induction of the p70 chain of the IL-2 receptor, allowing the cells to respond to added IL-2 by an as yet undefined signal transduction pathway that eventuated in release of bFGF. The results of immunohistologic studies of synovial tissues from rheumatoid joints, which displayed vascular staining for p55 and p70, support the observations in cell culture. Although these data do not prove that ECs synthesize p55 and p70 in vivo, it lends support to the concept that p55 and p70 can have a vascular distribution, and, potentially, vascular expression.
EC proliferation in cultures pretreated with IFN-a appeared to reflect several underlying mechanisms, principally involving the synthesis and release of bFGF. IFN-a increased intracellular levels of bFGF, but did not lead to detectable bFGF in culture supernatants. Addition of IL-2 to IFN-astimulated EC cultures led to release ofbFGF into the medium, and was followed by stimulation ofcell growth. In that bFGF is a polypeptide which lacks a signal sequence (5) (27) ; on the other hand, oligodendroglioma cells transfected with a p70-encoding cDNA can bind IL-2 with intermediate-affinity sites (; 2 nM), but are sensitive to the growth-promoting effect of the cytokine (28) . Indeed, the p70 chain, upon binding to IL-2, associates with at least a third molecule (in lymphoid cells, the tyrosine kinase p56Ick [12] ), that appears to participate in delivering the proliferative stimulus and may enhance the affinity of cytokine binding to the receptor (12) . Intracellular signal transduction mechanisms activated by IL-2 in endothelium are likely to be peculiar, with the final proliferative stimulus arising from bFGF/FGF receptor interaction.
Further studies will be required to assess the full spectrum of EC properties modulated by IFN-a/IL-2, but from the results thus far, it is likely that the effector mechanisms activated will provide insights into the pathogenesis of vascular reactions in certain immune/inflammatory settings. For example, perturbation of EC properties may underlie the observation that IFN-a and IL-2 together induce marked hemorrhagic and exudative lesions in an experimental model of Goodpasture's pneumonitis (16) . In another context, IFN-a/IL-2-induced release of bFGF can elicit EC production of proteases (29) , potentially facilitating blood vessel invasion as occurs in the rheumatoid pannus. On the other hand, our results raise many questions, such as the reason for the difference between the effect of IFN-a to cause regression of abnormal vascular structures (i.e., hemangiomas) (30) versus the angiogenic potential of this cytokine in the rabbit cornea model and its mitogenic properties for cultured endothelium. The neoplastic nature of hemangioma cells may account for this discrepancy; a relevant example of functional differences between neoplastic and normal endothelium is the proliferation of Kaposi's sarcoma cells in response to IL-1 (31 ) , which acts as a growth-inhibitory cytokine for normal ECs (9, 32) . Future studies will be required to fully elucidate the phenotype ofthe IFN-a/ IL-2-stimulated endothelial cell.
